


Estimated vaccination coverage with selected vaccines and doses* among adolescents aged 13-17 years, by survey year — National Immunization Survey-Teen, United States, 2006–2016†



Abbreviations: Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MenACWY = quadrivalent meningococcal conjugate vaccine; HPV = human papillomavirus; ACIP = Advisory Committee on Immunization Practices; APD = adequate provider data.

* ≥ 1 dose Tdap at or after age 10 years; ≥ 1 MenACWY: ≥ 1 dose MenACWY or meningococcal-unknown type vaccine; ≥ 2 MenACWY: ≥ 2 doses MenACWY or meningococcal-unknown type vaccine, calculated only among adolescents aged 17 years at time of interview. Does not include adolescents who received their first and only dose of MenACWY at or after 16 years of age; HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV) or bivalent (2vHPV). ACIP recommends 9vHPV, 4vHPV or 2vHPV for females and 9vHPV or 4vHPV for males. The routine ACIP recommendation was made for females in 2006 and for males in 2011.

† NIS-Teen implemented a revised adequate provider data definition (APD) in 2014, and retrospectively applied the revised APD definition to 2013 data. Estimates using different APD definitions may not be directly comparable. This graph includes two sets of estimates for 2013. NIS-Teen estimates from 2006–2013 connected with dashed lines are previously published estimates using the previous APD definition. NIS-Teen estimates from 2013–2016 connected with solid lines use the revised APD definition.